best peptides FAQ

Administer 250–500 micrograms subcutaneously near the injured pulley daily within 48 hours of injury onset. Early intervention maximizes angiogenesis during the acute inflammatory phase when VEGF receptors are upregulated. Combine with complete rest from crimp positions for the first 7–10 days. Peptides accelerate healing but don't eliminate the need for mechanical offloading. Most climbers report pain reduction within 10–14 days and return to low-intensity training at week 3–4 instead of the typical 6–8 week timeline.

Coordinate timing with your surgical team. Most research protocols begin peptides 7–10 days post-surgery once initial surgical inflammation has peaked and resolved. Starting too early can theoretically increase swelling at the surgical site; starting after week 2–3 means you've missed the critical proliferative phase of healing. The ideal window is when surgical drains are removed and active range-of-motion exercises begin. TB-500's anti-inflammatory properties can complement NSAIDs, but don't use it as a replacement without medical guidance. Surgical pain management serves a protective function.

Treat the infection first. Peptides promote angiogenesis and cell migration, which can theoretically accelerate bacterial spread if the wound is colonized. Standard infection management. Topical or systemic antibiotics, debridement if needed. Must precede peptide initiation. Once the wound shows clean granulation tissue and culture-negative status, peptides can support the epithelialization phase. TB-500 has demonstrated antimicrobial properties in vitro against certain bacterial strains, but that's not a substitute for proper wound care.

Administer TB-500 immediately. The proliferative phase (days 3–7) is when this peptide shows peak efficacy for soft tissue regeneration. You've missed the optimal window for BPC-157's angiogenic effects, but TB-500 still accelerates collagen deposition and reduces pain during the critical healing phase. Research protocols show benefit up to day 5 post-surgery.

Seek emergency medical evaluation first. Sudden sensorineural hearing loss is a medical urgency requiring audiometric testing and often immediate corticosteroid treatment within 72 hours. Thymalin or other peptides are adjunctive considerations, not replacements for standard care. If corticosteroids fail or are contraindicated, discussing immune-modulating peptides with an otolaryngologist familiar with research protocols is reasonable, but timing matters. Most animal studies show benefit only when administered within 48 hours of onset.

Administer TB-500 and GHK-Cu immediately if you're within the proliferative window (days 5–21). BPC-157's angiogenic benefit diminishes after day 10 since peak VEGF receptor expression occurs during early inflammation. Starting at week two captures the tail end of capillary formation but misses the optimal window. Focus on GHK-Cu to modulate ongoing collagen remodeling and prevent fibrotic irregularities that develop between weeks 3–6. TB-500 still supports lymphatic drainage if you're experiencing persistent edema.

Yes, but NSAIDs (ibuprofen, naproxen) suppress the COX-2 enzyme pathway that initiates inflammation. Which is also the signal that triggers collagen synthesis. Prolonged NSAID use (more than 7–10 days) can slow bone healing and potentially reduce peptide efficacy. If pain management requires NSAIDs, limit use to the first week post-injury, then transition to acetaminophen or non-pharmacological approaches. BPC-157's mechanism bypasses COX pathways, so the interaction is less direct than with TB-500 or GHK-Cu.

Reassess your ergonomic setup first. If you're still typing 8+ hours daily without wrist support, no peptide will outpace the ongoing damage. BPC-157's benefit is conditional on reducing the repetitive strain causing the inflammation. If ergonomics are optimised and symptoms persist, consider adding TB-500 to address nerve compression directly. Some cases involve significant median nerve demyelination that requires 8–12 weeks of combined therapy before measurable improvement in nerve conduction studies.

Limited benefit. Possibly none. NAD+ precursors like NMN support ALDH2 enzyme function during acetaldehyde production, which occurs while alcohol is being metabolized (0–6 hours post-consumption depending on intake volume). By the time you wake up hungover, acetaldehyde levels have already peaked and dropped. Administering NMN at that point addresses a metabolic bottleneck that no longer exists. Post-drinking NMN may support general cellular recovery via mitochondrial NAD+ restoration, but this is mechanistically separate from hangover symptom reduction.

Dihexa addresses synaptic connectivity, not photoreceptor regeneration. If central scotoma is due to geographic atrophy (dead photoreceptors in the macula), enhancing synaptic density in remaining peripheral vision pathways won't restore central vision. Dihexa might theoretically improve visual processing efficiency in intact areas, but no clinical data supports this application. It's speculative and not a substitute for low-vision rehabilitation.

Use BPC-157 for the ankle ligament damage and consider adding GHK-Cu systemically to support both sites. TB-500 addresses microvascular damage common to both injuries. Fracture healing is primarily osteoblast-driven, not peptide-responsive in the same way soft tissue is, but the surrounding soft tissue damage (periosteal bruising, muscle contusion) does benefit. Subcutaneous injection can be administered systemically rather than site-specific when multiple injury sites are present. Studies show comparable efficacy.

Preventative use lacks research support. Peptides function by modulating healing pathways that activate in response to injury, not by strengthening tissue in advance. There's no evidence that prophylactic BPC-157 or TB-500 administration reduces injury incidence in uninjured tissue. The better approach: address mechanical risk factors (quad/hamstring strength ratios, ankle dorsiflexion range) and equipment setup (binding DIN settings, boot stiffness) that actually predict injury occurrence. Peptides are repair tools, not prevention tools. If you're recovering from a prior season's injury and want to ensure full healing before the next season, complete a full peptide protocol during the off-season (6–8 weeks minimum), then allow 4–6 weeks of peptide-free tissue remodeling before returning to impact loading. The tissue strength gains from peptide-assisted healing need time to stabilize through normal mechanical loading without the peptide stimulus. The decision to use peptides for skiing injury recovery comes down to risk tolerance and access to quality compounds. If you're working with a sports medicine physician familiar with peptide research and have access to third-party tested peptides from a verified supplier like Real Peptides, the risk-benefit ratio shifts favourably for significant soft tissue injuries. Particularly those with documented poor healing rates like rotator cuff tears or hamstring avulsions. For minor strains and sprains that resolve within 4–6 weeks with standard care, the added complexity and cost likely isn't justified. The compounds work, but they're tools for specific scenarios, not universal solutions.

Peptides can't reverse established recession caused by bone loss, but they may slow progression and improve tissue quality. BPC-157 and thymosin beta-4 stimulate fibroblast activity and collagen deposition, which thickens existing gingival tissue and improves keratinization. The outer protective layer. A 2023 case series in the Journal of Esthetic and Restorative Dentistry reported using BPC-157 gel applied nightly for 12 weeks in patients with mild-to-moderate recession. Mean gingival thickness increased by 0.4mm, and recession depth stabilized with no further loss at one-year follow-up. This isn't tissue regeneration at the bone level, but it's meaningful improvement in tissue resilience.

Arnica (for bruising) and bromelain (a proteolytic enzyme that reduces swelling) operate through different mechanisms than peptides and can be used concurrently without interaction. Bromelain works by breaking down fibrin deposits that trap fluid in tissue. It complements BPC-157's vascular repair mechanism rather than interfering with it. Standard bromelain research doses are 500–1,000 mg taken 2–3 times daily on an empty stomach. Arnica's evidence base is weaker, but it's generally considered safe. Neither supplement affects peptide stability or absorption when dosed separately.

Start during the inflammatory phase. Within 48–72 hours post-injury. BPC-157 and TB-500 don't suppress inflammation entirely; they modulate it toward resolution while simultaneously initiating proliferative processes. Delaying peptide administration until week two means missing the critical window when fibroblast recruitment and angiogenesis determine scar tissue quality versus functional tissue restoration. Research models administering BPC-157 within 24 hours of induced Achilles tendon rupture showed superior biomechanical strength at 14 days compared to delayed administration groups.

Add KPV to your protocol. Reflux-induced laryngeal damage creates a vicious cycle: acid erodes the epithelial barrier, allowing deeper tissue damage, which triggers more inflammation and slows healing. KPV restores tight junction proteins (occludin, claudin) that seal the epithelial barrier, reducing acid penetration while BPC-157 repairs underlying structural damage. Dosing: 500 mcg KPV daily alongside standard BPC-157 protocol.

Start Selank immediately at 300–600mcg daily and use strategic light exposure during the flight. You've lost the window for pre-shift pineal priming with Thymalin or Epitalon, so focus on cortisol management and light-based SCN cueing. Wear blue-blocking glasses during the flight's sleep window (aligned with night at your destination), remove them during destination daytime, and dose Selank in the morning to blunt the cortisol spike that occurs when you force wakefulness against your internal clock.

Mild redness at the injection site within 1–2cm is normal histamine response and resolves in 24 hours. Spreading redness beyond 3cm, warmth, or purulent discharge indicates potential bacterial contamination or endotoxin reaction. Stop administration immediately. This underscores why third-party endotoxin testing matters: bacterial lipopolysaccharides from impure synthesis trigger systemic inflammation that mimics infection.

Post-refractive surgery neurotrophic keratopathy. Corneal nerve damage causing severe dry eye symptoms disproportionate to clinical signs. Responds poorly to standard therapy because the pathology is neurogenic, not inflammatory. Thymosin Beta-4 promotes corneal nerve regeneration through neurotrophin upregulation (NGF, BDNF) demonstrated in animal models of corneal denervation injury. Anecdotal reports from ophthalmologists using compounded Tβ4 in post-LASIK patients describe symptom resolution within 4–8 weeks where previous therapies (including autologous serum) provided minimal relief. No controlled trials exist for this specific indication, but the mechanistic rationale is sound: if the primary deficit is nerve function rather than tear production or inflammation, a neurotropic peptide addresses the root cause.

Taper vestibular suppressants (meclizine, diazepam, antihistamines) before starting neuroplasticity-focused peptide protocols. Suppressants inhibit the neural activity required for compensation. Continuing them while using Cerebrolysin or Dihexa contradicts the mechanism you're trying to enhance. Work with a prescribing physician to reduce suppressant doses gradually over 7–14 days while initiating peptide therapy. Short-term nausea or dizziness during the taper is expected as your brain adjusts to unfiltered vestibular input.